The long-term cost-effectiveness of once-weekly semaglutide 1 mg vs. dulaglutide 3 mg and 4.5 mg in the UK.

Adie ViljoenBarrie ChubbSamuel J P MalkinSasha BerryBarnaby HuntStephen C Bain

Published in: The European journal of health economics : HEPAC : health economics in prevention and care (2022)

Semaglutide 1 mg represents a cost-effective treatment vs. dulaglutide 3 mg and 4.5 mg for type 2 diabetes from a healthcare payer perspective in the UK.

Keyphrases

type diabetes
healthcare
cardiovascular disease
metabolic syndrome
insulin resistance
skeletal muscle
adipose tissue
weight loss
health information
smoking cessation